Epigenetics is a stream of genetics that involves the study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect the cellular ability to read genes without being affected by changes in the genotype Epigenetics results into changes in the organisms' phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. The global epigenetics market accounted for $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023.
Epigenetic alterations are essential for development; they are dynamic and change with respect to the environmental stimuli. However, these changes can also be stable and could be passed on from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, thereby making it one of the most crucial fields of developmental genetics and molecular biology.
High incidence of cancer; increase in R&D activities; surge in investments funding, rise in epigenetic applications for non-oncology diseases; and growth in partnership between academic, pharmaceutical, and biotechnology companies cumulatively supplement the growth of the global epigenetics market. However, high cost of instruments and lack of trained professionals impede the growth of this market. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.
The epigenetics market is segmented based on product, application, end user, and geography. Based on product, it is divided into enzymes, kits & assays, instruments, and reagents. Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits & assays are further subdivided into bisulfite conversion kits, chip-seq kits, deep sequencing kits, methyltransferase assays, histone assays, immunoprecipitation kits & other epigenetic kits. Based on instruments, the market is further sub segmented into mass spectrometers, next-generation sequencers, qPCRs, and sonicators & other instruments. Reagents are further divided into antibodies, buffers, histones, magnetic beads, primers, and other epigenetics reagents.
On the basis application, the market is classified into oncology and non-oncology. Oncology is further sub segmented into solid tumors & liquid tumors. Non-oncology applications include inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global epigenetics market and the current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on application assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY PLAYERS PROFILED
Abcam plc.
Illumina
QIAGEN N.V.
Epizyme, Inc.
New England Biolabs, Inc.
Merck & Co.,
Thermo Fisher Scientific, Inc.
Active Motif,
Diagenode, Inc.
Zymo Research Corporation
KEY MARKET SEGMENTS
By Product
Enzymes
DNA Ligases
DNA Polymerases
Other DNA-modifying Enzymes
Acetylases
Methyltransferases
Other Protein-modifying Enzymes
Reverse Transcriptase
RNA Ligases
Other RNA-modifying Enzymes
Kits & Assays
Bisulfite Conversion Kits
Chip-seq Kits
Deep Sequencing Kits
Methyltransferase Assays
Histone Assays
Immunoprecipitation Kits
Other Epigenetic Kits
Instruments
Mass Spectrometers
Next-generation Sequencers
qPCRs
Sonicators
Other Instruments
Reagents
Antibodies
Buffers
Histones
Magnetic Beads
Primers
Other Epigenetics Reagents
By Application
Oncology
Solid Tumors
Liquid Tumors
Non-oncology
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases
Developmental Biology
Drug Discovery
Others
By End User
Academic & Research Institutes
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
The other players in the value chain include (profiles not included in the report)
Domainex
CellCentric Ltd.
Chroma Therapeutics Ltd.
Eisai Co. Ltd.
Novartis International AG
Oncolys Biopharma Inc.
Syndax Pharmaceuticals, Inc.
Valirx plc.